Meeting: 2018 ASCO Annual Meeting Track: Melanoma/Skin Cancers Abstract number: 9504 Authors: Reinhard Dummer, Paolo Antonio Ascierto, Helen Gogas, et. al. Background: Combined BRAF/MEK inhibitor therapy is standard of care in advanced BRAFV600-mutant melanoma. COLUMBUS Part 1 evaluated ENCO 450 mg once daily (QD) + BINI 45 mg twice daily (BID;COMBO450) vs VEM...
Pro zobrazení tohoto obsahu je třeba být přihlášen.